HYDERABAD, Jan 30 (Reuters) - Indian biopharma company Biocon (BION.NS), opens new tab reported third-quarter revenue on Thursday that fell about 3% when compared with the year-earlier period, which ...

At around 10:42 a.m., Biocon shares were up 1.51 per cent, or Rs 3.6, at Rs 242.05 apiece on BSE. The market capitalisation ...

Biocon has named Peter Bains its next CEO as the company looks to expand its presence in North America and beyond. As part of the move, which became effective Monday, Bains will step down from ...

BRIDGEWATER, N.J. and BENGALURU, India, April 10, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the U.S. Food and ...

Profit rises 71% YoY to Rs 144 crore Biocon Biologics share which constitutes 45% of revenues reported 29% YoY growth to Rs ...

Biocon’s insulin copycat aspart hit another roadblock as the FDA issued a complete response letter (CRL), saying the Malaysia production facility still must undergo a pre-approval inspection to ...

Biocon Generics (BGI), a wholly owned subsidiary of Indian biopharmaceutical company Biocon Ltd, has unveiled its new manufacturing facility in Cranbury, New Jersey, US. Biocon acquired the site from ...

Bengaluru: Biocon is doubling down on its internal operations with fresh capital support to two key subsidiaries. The company completed the acquisition of preference shares in both entities on March 3 ...

Biocon Limited (BSE: 532523; NSE: BIOCON) today announced the appointment of Shreehas Tambe as its Chief Executive Officer & Managing Director, effective April 1, 2026, following approvals from the ...

According to Bloomberg, 3.19 million shares were traded in multiple block deals. Buyers and sellers of the transactions were not known ...

Biocon Ltd has received approval from Health Canada for its biosimilars, Bosaya and Vevzuo, intended for treating osteoporosis and cancer-related bone complications. This approval underscores Biocon's ...